Skip to main content

Table 3 Baseline Characteristics of Subset 2 data by Group

From: A randomized, double-blind, placebo-controlled, multicenter study assessing the efficacy of magnesium oxide monohydrate in the treatment of nocturnal leg cramps

 

MOMH

(N = 64)

Placebo

(N = 65)

P Value

Demographics

Gender Female n (%)

52 (81.3)

51 (78.5)

0.827

Age (years) mean (±SD)

60.4 (±10.9)

59.1 (±10.1)

0.517a

Weight (kg) mean (±SD)

75.1 (±11.8)

74.3 (±13.1)

0.583

Height (cm) mean (±SD)

165.9 (±7.7)

166.2 (±7.8)

0.278

BMI (kg/m2) mean (±SD)

27.3 (±4.1)

26.9 (±4.8)

0.395a

Physiological parameters

Systolic blood pressure (mmHg) mean (±SD)

127.6 (±10.9)

127.7 (±9.6)

0.826a

Diastolic blood pressure (mmHg) mean (±SD)

78.8 (±6.7)

77.5 (±6.2)

0.154a

Heart rate (beats/min) mean (±SD)

72.0 (±6.9)

71.7 (±6.6)

0.749a

Baseline efficacy parameters

NLC frequency (num/week) mean (±SD)

5.8 (±5.7)

7.3 (±9.5)

0.753a

NLC duration (sec/week) mean (±SD)

311.4 (±242.9)

340.7 (±247.1)

0.410a

NLC pain (mean VAS/week) mean (±SD)

6.5 (±1.6)

6.8 (±1.5)

0.252

Sleep quality (mean cumulative score/week) mean (±SD)

13.0 (±3.7)

12.5 (±3.8)

0.451

Quality of life subscales:

- Physical functioning

58.6 (±24.2)

60.2 (±26.9)

0.934a

- Role limitation due to physical health

38.3 (±44.5)

40.8 (±43.4)

0.616a

- Role limitation due to emotional problems

37.0 (±44.9)

33.9 (±43.1)

0.696a

- Vitality

45.4 (±14.2)

45.5 (±12.4)

0.783a

- Mental health

49.2 (±13.8)

49.2 (±12.0)

0.879a

- Social functioning

60.4 (±15.7)

57.7 (±15.3)

0.457a

- Body Pain

46.0 (±18.2)

46.0 (±17.7)

0.921a

- General health

44.3 (±13.1)

45.4 (±8.8)

0.580a

  1. BMI body mass index, MOMH magnesium oxide monohydrate, NLC nocturnal leg cramps, SD standard deviation, VAS visual analogue scale
  2. Note: Variables marked with a were not normally distributed. ANOVA and ANCOVA on ranks were performed for comparisons of these variables